Contact
searchSearch
HMP Global

Conference Coverage

Ed Loftus
Video
Edward Loftus, MD, on Upper GI Crohn's Disease
01/07/2025
Edward V. Loftus, Jr., MD
Dr Loftus explains how Crohn's disease can affect the upper gastrointestinal system, from the mouth to the duodenum, and the options for treating this rare presentation.
Dr Loftus explains how Crohn's disease can affect the upper gastrointestinal system, from the mouth to the duodenum, and the options for treating this rare presentation.
Dr Loftus explains how Crohn's...
01/07/2025
Advances in Inflammatory Bowel Disease Network
Gil Y. Melmed, MD
Video
Gil Melmed, MD, on Noninvasive Monitoring in IBD
01/03/2025
Dr Melmed reviews the noninvasive options available to clinicians to monitor disease activity in inflammatory bowel disease, including biomarkers, stool testing, and imaging modalities.
Dr Melmed reviews the noninvasive options available to clinicians to monitor disease activity in inflammatory bowel disease, including biomarkers, stool testing, and imaging modalities.
Dr Melmed reviews the...
01/03/2025
Advances in Inflammatory Bowel Disease Network
Conference Coverage
Subcutaneous Mirikizumab Found Tolerable After Hypersensitivity Reaction to IV Infusion
12/10/2024
Jessica Garlewicz
A case study published in The American Journal of Gastroenterology presented at Advances in Inflammatory Bowel Diseases (AIBD), highlights a successful rechallenge with subcutaneous mirikizumab.
A case study published in The American Journal of Gastroenterology presented at Advances in Inflammatory Bowel Diseases (AIBD), highlights a successful rechallenge with subcutaneous mirikizumab.
A case study published in The...
12/10/2024
Advances in Inflammatory Bowel Disease Network
Conference Coverage
Mirikizumab Improves Quality of Life in Crohn’s Disease Patients With and Without Prior Biologic Failure
12/10/2024
Jessica Garlewicz
A post hoc analysis of the phase 3 VIVID-1 trial has revealed that mirikizumab, an anti-IL-23p19 antibody, significantly improves health-related quality of life in patients with moderately-to-severely active Crohn’s disease.
A post hoc analysis of the phase 3 VIVID-1 trial has revealed that mirikizumab, an anti-IL-23p19 antibody, significantly improves health-related quality of life in patients with moderately-to-severely active Crohn’s disease.
A post hoc analysis of the phase...
12/10/2024
Advances in Inflammatory Bowel Disease Network
Conference coverage
GLP-1 Agonists Show Promise in Managing Short Gut Syndrome for IBD Patients
12/09/2024
Riya Gandhi, MA
Could diabetes and obesity medications offer new hope for inflammatory bowel disease patients with short gut syndrome?
Could diabetes and obesity medications offer new hope for inflammatory bowel disease patients with short gut syndrome?
Could diabetes and obesity...
12/09/2024
Advances in Inflammatory Bowel Disease Network
Conference coverage
Medical Trauma in IBD: Addressing an Overlooked Challenge in Young Adults
12/09/2024
Riya Gandhi, MA
Unpacking the hidden burden of medical trauma, this study charts a path toward better care for young adults with inflammatory bowel disease.
Unpacking the hidden burden of medical trauma, this study charts a path toward better care for young adults with inflammatory bowel disease.
Unpacking the hidden burden of...
12/09/2024
Advances in Inflammatory Bowel Disease Network
Conference coverage
Upadacitinib Shows Promise for Refractory Lymphocytic Colitis
12/09/2024
Riya Gandhi, MA
Upadacitinib may offer a new treatment avenue for refractory lymphocytic colitis, according to an abstract presented at Advances in Inflammatory Bowel Diseases.
Upadacitinib may offer a new treatment avenue for refractory lymphocytic colitis, according to an abstract presented at Advances in Inflammatory Bowel Diseases.
Upadacitinib may offer a new...
12/09/2024
Advances in Inflammatory Bowel Disease Network
Conference coverage
Efficacy of Mirikizumab in Moderate-to-Severe Crohn’s Disease
12/05/2024
Jessica Garlewicz
Further studies are needed to explore its effects in patients with ileal-only Crohn’s disease, due to the limited sample size of these patients in the Phase 3 VIVID-1 Study.
Further studies are needed to explore its effects in patients with ileal-only Crohn’s disease, due to the limited sample size of these patients in the Phase 3 VIVID-1 Study.
Further studies are needed to...
12/05/2024
Advances in Inflammatory Bowel Disease Network
Video
Remo Panaccione, MD, on the GRAVITI Trials of Guselkumab in Crohn's Disease
12/02/2024
Dr Panaccione reviews the latest trial results for guselkumab in treating Crohn's disease, showing that both IV and subcutaneous induction are superior to placebo.
Dr Panaccione reviews the latest trial results for guselkumab in treating Crohn's disease, showing that both IV and subcutaneous induction are superior to placebo.
Dr Panaccione reviews the latest...
12/02/2024
Advances in Inflammatory Bowel Disease Network
Conference Coverage
Upadacitinib Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
11/15/2024
Clinical remission based on stool frequency/abdominal pain score (SF/APS) ranged from 78.3% to 82.9% for UPA15 and from 84.7% to 76.6% for UPA30.
Clinical remission based on stool frequency/abdominal pain score (SF/APS) ranged from 78.3% to 82.9% for UPA15 and from 84.7% to 76.6% for UPA30.
Clinical remission based on...
11/15/2024
Advances in Inflammatory Bowel Disease Network

Latest News

News
Early Response to Upadacitinib Predicts Long-Term Improvements in Crohn’s Disease
04/03/2025
Jessica Garlewicz
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response achieved higher rates of clinical remission and reductions in fatigue and impairment.
Patients with early response...
04/03/2025
Advances in Inflammatory Bowel Disease Network
News
NAFLD Linked to Worse Clinical Outcomes in Hospitalized Crohn’s Disease Patients
04/03/2025
Jessica Garlewicz
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting nonalcoholic fatty liver disease.
A new study examined 792,409 hospitalizations for Crohn's disease, of which 26,229 (3.3%) involved patients with coexisting nonalcoholic fatty liver disease.
A new study examined 792,409...
04/03/2025
Gastroenterology
FDA Alert
FDA Approves Both SC and IV Guselkumab for Crohn's Disease Among Adult Patients
03/24/2025
Rebecca Mashaw
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last year's approval for ulcerative colitis and the first approval for subcutaneous and intravenous formulations to induce remission in adult patients with moderately to severely active Crohn's disease.
This clearance follows last...
03/24/2025
Advances in Inflammatory Bowel Disease Network
News
Risankizumab Shows Efficacy in Treating Pouch Complications
03/19/2025
Rebecca Mashaw
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of patients with Crohn’s disease of the pouch experienced clinical remission after 12 weeks of therapy with the IL-23 inhibitor.
Half of a small cohort of...
03/19/2025
Advances in Inflammatory Bowel Disease Network
News
Ozanimod Effective in Biologic-Exposed UC Patients
03/17/2025
Jessica Garlewicz
Some patients in the open-label extension of TRUE NORTH required more time to respond, but efficacy appears durable up to 3 years.
Some patients in the open-label extension of TRUE NORTH required more time to respond, but efficacy appears durable up to 3 years.
Some patients in the open-label...
03/17/2025
Advances in Inflammatory Bowel Disease Network
News
Upadacitinib Demonstrates Improved Outcomes Over Tofacitinib in Ulcerative Colitis
03/17/2025
Jessica Garlewicz
One year after initiation, patients receiving upadacitinib were at significantly lower risk of colectomy than those treated with tofacitinib.
One year after initiation, patients receiving upadacitinib were at significantly lower risk of colectomy than those treated with tofacitinib.
One year after initiation,...
03/17/2025
Advances in Inflammatory Bowel Disease Network
News
Global Incidence of Pediatric-Onset Inflammatory Bowel Disease Continues to Rise
03/14/2025
Jessica Garlewicz
Study findings highlight the importance of early diagnosis, improved treatment strategies, and equitable access to care for children affected by pediatric inflammatory bowel disease worldwide.
Study findings highlight the importance of early diagnosis, improved treatment strategies, and equitable access to care for children affected by pediatric inflammatory bowel disease worldwide.
Study findings highlight the...
03/14/2025
Advances in Inflammatory Bowel Disease Network
News
Challenges and Advances in the Management of Fistulizing Perianal Crohn’s Disease
03/13/2025
Jessica Garlewicz
Surgical interventions are often essential when biologics alone prove inadequate in the treatment of fistulizing perianal Crohn's disease.
Surgical interventions are often essential when biologics alone prove inadequate in the treatment of fistulizing perianal Crohn's disease.
Surgical interventions are often...
03/13/2025
Advances in Inflammatory Bowel Disease Network
News
Assessing Long-Term Outcomes of Crohn’s Disease Following Mucosal and Transmural Healing
03/13/2025
Rebecca Mashaw
Adopting standardized measures and use of less invasive assessment methods should enhance patient monitoring.
Adopting standardized measures and use of less invasive assessment methods should enhance patient monitoring.
Adopting standardized measures...
03/13/2025
Advances in Inflammatory Bowel Disease Network
News
Novel Therapies and Mucosal Healing in Crohn’s Disease
02/26/2025
Rebecca Mashaw
With mucosal healing now a primary goal of Crohn's disease (CD) treatment, investigators sought to compare the efficacy of novel therapies in achieving this goal in comparison to placebo.
With mucosal healing now a primary goal of Crohn's disease (CD) treatment, investigators sought to compare the efficacy of novel therapies in achieving this goal in comparison to placebo.
With mucosal healing now a...
02/26/2025
Advances in Inflammatory Bowel Disease Network

Latest Podcasts

IBD Drive time logo
Podcast
IBD Drive Time: Freddy Caldera, DO, on Disease Prevention in IBD
03/17/2025
Millie D. Long, MD, MPH; Freddy Caldera, DO
Freddy Caldera, DO, PhD, and IBD Drive Time cohost Millie Long, MD, discuss the new AGA best practice advice on preventing diseases and monitoring for complications in patients with inflammatory bowel disease.
Freddy Caldera, DO, PhD, and IBD Drive Time cohost Millie Long, MD, discuss the new AGA best practice advice on preventing diseases and monitoring for complications in patients with inflammatory bowel disease.
Freddy Caldera, DO, PhD, and IBD...
03/17/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Detecting and Managing Anorectal Cancer
03/04/2025
Raymond Cross, MD; Millie D. Long, MD, MPH; Jessica Korman
Andrea Bafford, MD, and Jessica Korman, MD, join Drs Raymond Cross and Millie Long to review the challenges of detecting, diagnosing, and managing anorectal cancer among patients with inflammatory bowel disease.
Andrea Bafford, MD, and Jessica Korman, MD, join Drs Raymond Cross and Millie Long to review the challenges of detecting, diagnosing, and managing anorectal cancer among patients with inflammatory bowel disease.
Andrea Bafford, MD, and Jessica...
03/04/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcasts
IBD Drive Time: Jami Kinnucan, MD, on Using Cannabis in IBD
02/12/2025
Jami Kinnucan; Raymond Cross, MD; Millie D. Long, MD, MPH
Jami Kinnucan, MD, reviews the facts and fallacies about the use of cannabis for the treatment of inflammatory bowel disease, and how to discuss the issue with patients, with IBD Drive Time hosts Raymond Cross, MD, and Millie Long, MD.
Jami Kinnucan, MD, reviews the facts and fallacies about the use of cannabis for the treatment of inflammatory bowel disease, and how to discuss the issue with patients, with IBD Drive Time hosts Raymond Cross, MD, and Millie Long, MD.
Jami Kinnucan, MD, reviews the...
02/12/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Lin Chang, MD, on IBS in IBD
01/27/2025
Raymond Cross, MD
Dr Lin Chang joins hosts Raymond Cross, MD, and Millie Long, MD, to discuss how patient with inflammatory bowel disease may also have underlying irritable bowel syndrome, how to diagnose the condition, and the best options for treatment.
Dr Lin Chang joins hosts Raymond Cross, MD, and Millie Long, MD, to discuss how patient with inflammatory bowel disease may also have underlying irritable bowel syndrome, how to diagnose the condition, and the best options for treatment.
Dr Lin Chang joins hosts Raymond...
01/27/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Sara Horst, MD, on the Best of ACG
01/20/2025
Raymond Cross, MD
Drs Ray Cross and Millie Long discuss with guest Dr Sara Horst the best presentations and abstracts on inflammatory bowel disease from the American College of Gastroenterology scientific meeting held in October.
Drs Ray Cross and Millie Long discuss with guest Dr Sara Horst the best presentations and abstracts on inflammatory bowel disease from the American College of Gastroenterology scientific meeting held in October.
Drs Ray Cross and Millie Long...
01/20/2025
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Frank Scott, MD, on the AGA Guidelines for Ulcerative Colitis Management
12/30/2024
In this IBD Drive Time podcast, Dr Frank Scott from the University of Colorado and host Dr Raymond Cross discuss updates in the AGA guidelines for ulcerative colitis.
In this IBD Drive Time podcast, Dr Frank Scott from the University of Colorado and host Dr Raymond Cross discuss updates in the AGA guidelines for ulcerative colitis.
In this IBD Drive Time podcast,...
12/30/2024
Advances in Inflammatory Bowel Disease Network
Millie Long
Video
Millie Long, MD, on Comparative Effectiveness in Ulcerative Colitis
10/21/2024
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation from the AIBD regional meeting on using comparative effectiveness data to choose from among the growing number of therapies for treating ulcerative colitis.
Dr Long reviews her presentation...
10/21/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Drs James Lewis and Laura Raffals on SPARC
10/21/2024
Dr Raymond Cross hosts Drs James Lewis and Laura Raffals in a discussion of SPARC, a study of adults with inflammatory bowel disease in which patients are followed prospectively to collect data about to allow prediction of disease course and...
Dr Raymond Cross hosts Drs James Lewis and Laura Raffals in a discussion of SPARC, a study of adults with inflammatory bowel disease in which patients are followed prospectively to collect data about to allow prediction of disease course and...
Dr Raymond Cross hosts Drs James...
10/21/2024
Advances in Inflammatory Bowel Disease Network
Freddy Caldera
Podcast
Freddy Caldera, DO, on the RSV Vaccine for Patients With IBD
10/11/2024
Freddy Caldera
Dr Caldera, from the University of Wisconsin School of Medicine, provides an overview of the risks of respiratory syncytial virus to older adults, including patients with IBD, and the importance of ensuring patients receive this vaccine along...
Dr Caldera, from the University of Wisconsin School of Medicine, provides an overview of the risks of respiratory syncytial virus to older adults, including patients with IBD, and the importance of ensuring patients receive this vaccine along...
Dr Caldera, from the University...
10/11/2024
Advances in Inflammatory Bowel Disease Network
IBD Drive time logo
Podcast
IBD Drive Time: Updates on the PIANO Study of IBD and Pregnancy
10/07/2024
IBD Drive Time Hosts Millie Long, MD, and Raymond Cross, MD, discuss new recommendations for managing inflammatory bowel disease among pregnant patients or those wanting to conceive, resulting from updates to the landmark PIANO study. 
IBD Drive Time Hosts Millie Long, MD, and Raymond Cross, MD, discuss new recommendations for managing inflammatory bowel disease among pregnant patients or those wanting to conceive, resulting from updates to the landmark PIANO study. 
IBD Drive Time Hosts Millie...
10/07/2024
Advances in Inflammatory Bowel Disease Network

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use